Pechačová Z, Zemanová M, Končeková J
Klin Onkol. 2018 Winter;31(6):439-447. doi: 10.14735/amko2018439.
Radiotherapy (RT) is a mainstay of oncology treatment in both curative and palliative situations. With respect to palliative and supportive care, RT improves local control of disease and relieves symptoms, particularly pain, compression of surrounding structures, and/or bleeding. The aim here was to evaluate the effects and toxicity of palliative RT in our department from April 2015 to April 2018.
During this period, 338 cases received palliative RT, representing approximately one third of indications for this treatment method. We evaluated selected subgroups of patients: those with advanced lung cancer, bone metastases, or soft tissue metastases. Patients were irradiated by the IMRT (intensity modulated radiation therapy) technique using the TomoTherapy HD (Accuray, USA) platform.
Palliative RT for primary lung cancer was performed for 29 patients. Of these, symptoms were relieved in 22 patients (76%) and local control (confirmed by imaging) was achieved in 19 patients (66%). Treatment-related toxicity was acceptable. Overall, 104 patients received irradiation for bone metastases; pain relief was achieved in more than 75% of cases. Another 71 patients were irradiated to treat soft tissue metastases; symptoms were relieved in 60% of cases. Treatment-related toxicity in our patients was lower than reported previously, suggesting improved quality of life for patients irradiated using modern RT technologies.
Palliative RT provided excellent symptom control in our patients, with minimal toxicity. Thus, RT is an effective and easy-to-use method for many palliative indications. Key words: palliative care - radiotherapy - lung neoplasms - neoplasm metastasis - bone metastases - pain management The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers. Submitted: 28. 8. 2018 Accepted: 29. 10. 2018.
放射治疗（RT）在根治性和姑息性肿瘤治疗中均是主要手段。在姑息性和支持性治疗方面，放射治疗可改善疾病的局部控制并缓解症状，尤其是疼痛、周围结构受压和/或出血。本研究旨在评估2015年4月至2018年4月期间我科姑息性放射治疗的效果和毒性。
在此期间，338例患者接受了姑息性放射治疗，约占该治疗方法适应证的三分之一。我们评估了部分选定的患者亚组：晚期肺癌、骨转移或软组织转移患者。患者采用IMRT（调强放射治疗）技术，使用TomoTherapy HD（美国Accuray公司）平台进行照射。
对29例原发性肺癌患者进行了姑息性放射治疗。其中，22例患者（76%）症状得到缓解，19例患者（66%）实现了局部控制（经影像学证实）。治疗相关毒性可接受。总体而言，104例患者接受了骨转移照射；超过75%的病例疼痛得到缓解。另外71例患者接受了软组织转移照射；60%的病例症状得到缓解。我们患者的治疗相关毒性低于先前报道，表明使用现代放射治疗技术照射的患者生活质量有所提高。
姑息性放射治疗在我们的患者中提供了出色的症状控制，毒性极小。因此，放射治疗是许多姑息性适应证的有效且易于使用的方法。关键词：姑息治疗 - 放射治疗 - 肺肿瘤 - 肿瘤转移 - 骨转移 - 疼痛管理 作者声明他们在研究中使用的药物、产品或服务方面没有潜在的利益冲突。编辑委员会声明该手稿符合ICMJE关于生物医学论文的建议。提交日期：2018年8月28日 接受日期：2018年10月29日
